新型冠状病毒肺炎药物预防、诊断、治疗与出院管理临床实践指南:证据评价(一)

Evidence-based clinical practice guideline for chemoprophylaxis,diagnosis,treatments,and discharge management of COVID-19:evidence evaluation(1)

目的对本团队已发表新型冠状病毒肺炎药物预防、诊断、治疗与出院管理临床实践指南纳入证据中的系统评价部分进行再评价。方法指南中的证据检索数据库/资源为PubMed、The Cochrane Library、Embase、中国知网和万方数据库,补充检索部分感染或呼吸相关的重要医学期刊、预印本平台和临床试验注册中心收集新型冠状病毒肺炎治疗相关系统评价/Meta分析。检索时间为2019年12月1日至2020年7月8日。本研究采用AMSTAR 2工具评价所纳入系统评价的方法学质量。结果共纳入6篇系统评价/Meta分析,4篇涉及药物治疗,2篇为免疫治疗。AMSTAR 2评价结果显示1篇研究方法学质量为高,3篇为中等,1篇为低,1篇为极低,方法学不足主要表现在方案与注册、分析方法及资金来源等方面。结论现有新型冠状病毒肺炎治疗相关系统评价的方法学质量为极低到高等,部分结论尚不能确定,仍需大样本、长期随访的高质量研究来证实。

Objective To re-evaluate the systematic reviews of the evidence included in the team's published clinical practice guidelines for COVID-19 drug prevention,diagnosis,treatment,and discharge management.Methods we were electronically searched to collect systematic reviews/meta-analysis of COVID-19 treatment from PubMed,The Cochrane Library,Embase,CNKI and WanFang databases,and important medical journals,preprinted platform and clinical trial registry.The retrieval time was December 1,2019 to July 8,2020.AMSTAR 2 tool was used to evaluate the methodological quality of the included systematic reviews.Results A total of 6 systematic reviews/meta-analyses were included,four were drug therapy and two were immunotherapy.The evaluation results of AMSTAR 2 showed that the methodological quality of 1 study was high,3 were moderate,1 was low,and 1 was extremely low.Methodology deficiencies are mainly reflected in the scheme and registration,analysis methods and funding sources,etc.Conclusions The methodological quality of the systematic reviews of COVID-19 treatment range from extremely low to high,and some conclusions cannot be determined.High-quality studies with large samples and long-term follow-up are still needed to confirm this.